Berlin-based Selfapy has secured backing from High-Tech Grunderfonds in a €7 million round intended to shore up domestic growth and kickstart European expansion of its digital therapeutics platform addressing multiple mental health disorders.
The round was led by ADHD treatment developer Medice Arzneimittel with participation from SHS, Think.Health Ventures, and IBB Ventures among others. The last three investors together with HTGF have all backed Selfapy on previous occasions.
Selfapy provides online self-help courses for patients with depression and anxiety disorders. The digital treatments have been sanctioned by Germany for reimbursement under all statutory health insurance policies.
The platform was expanded a short while ago to include new treatments for binge-eating disorder and bulimia. All Selfapy treatments use cognitive behavioural therapy, and the platform has been listed in Germany's federal medical device directory.
Selfapy was founded in Berlin by Nora Blum and Katrin Bermbach. It's thought around 18 million German residents experience a mental illness, with wait lists for support lasting as long as six months.